Actively Recruiting
Measuring Oncological Value of Exercise and Statin
Led by Tampere University Hospital · Updated on 2025-06-27
240
Participants Needed
1
Research Sites
248 weeks
Total Duration
On this page
Sponsors
T
Tampere University Hospital
Lead Sponsor
T
Tampere University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to unsupervised exercise. In addition, the investigators are investigating whether the use of atorvastatin combined with guided group exercise training would further improve the response to cancer treatment.
CONDITIONS
Official Title
Measuring Oncological Value of Exercise and Statin
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient has metastatic prostate, breast, ovarian, or kidney cancer confirmed by histology and imaging and is starting first-line cancer drug treatment
- Prostate cancer patients are starting docetaxel or second-generation antiandrogen treatment
- Breast cancer patients are starting first-line metastatic breast cancer treatment regardless of hormone status
- Kidney cancer patients are starting first-line treatment with TKI monotherapy, IO monotherapy, or combination therapy
- Ovarian cancer patients have stage III or IV disease and are starting chemotherapy
- Patient agrees to participate and signs written informed consent
- Adults 18 years or older; women for breast, ovarian, and kidney cancer; men for prostate and kidney cancer
- Women must use reliable contraception during the intervention
You will not qualify if you...
- High risk of bone fractures
- Unable to perform physical exercise or unsuitable for cancer drug treatment
- Poor cooperation ability due to psychological reasons
- Active use of cholesterol-lowering drugs (except in separate statin-user group)
- Severe liver or kidney failure
- Past troublesome side effects from cholesterol medications
- Continuous use of medications interacting with atorvastatin during the study
- Special groups per EU Clinical Trials Regulation (e.g., pregnant or lactating women)
- For patients already using statins: exclusion also includes high fracture risk, inability to exercise, poor cooperation, severe liver or kidney failure, and special groups as above
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tampere University Hospital
Tampere, Länsi-Suomi, Finland, 33520
Actively Recruiting
Research Team
T
Teemu Murtola, MD PhD Prof
CONTACT
J
Jorma Sormunen, MD PhD MBA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here